Wells Fargo Downgrades OncoMed Pharmaceuticals (OMED) to Market Perform Following Acquisition Offer
Tweet
Share
E-mailGet Alerts OMED Hot Sheet
Price: $0.89 --0%
Rating Summary:
1 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 14 | New: 17
Rating Summary:
1 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 14 | New: 17
Join SI Premium – FREE
Wells Fargo analyst Jim Birchenough downgraded OncoMed Pharmaceuticals (NASDAQ: OMED) from Outperform to Market Perform with a price target of $1.50 (from $8.00).
For an analyst ratings summary and ratings history on OncoMed Pharmaceuticals click here. For more ratings news on OncoMed Pharmaceuticals click here.
Shares of OncoMed Pharmaceuticals closed at $1.11 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rentokil Initial (RTO) PT Lowered to $35 at Oppenheimer
- Stifel Downgrades Shield Therapeutics PLC (STX:LN) to Hold
- Alkem Laboratories Ltd (ALKEM:IN) PT Raised to INR4,915 at HSBC
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesRelated Entities
Wells FargoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
